Proteomics Analysis of the Proliferative Effect of Low-Dose Ouabain on Human Endothelial Cells
-
- Qiu Jie
- Department of Geriatrics, Shandong University Qilu Hospital Department of Intensive Care Unit, Shandong Qianfoshan Hospital
-
- Gao Hai-Qing
- Department of Geriatrics, Shandong University Qilu Hospital
-
- Zhou Rui-Hai
- Department of Geriatrics, Shandong University Qilu Hospital
-
- Liang Ying
- Department of Intensive Care Unit, Shandong Qianfoshan Hospital
-
- Zhang Xu-Hua
- Experimental Center of Molecular Biology, Shandong University School of Medicine
-
- Wang Xu-Ping
- The Key Laboratory of Cardiovascular Remodeling and Function Research, Shandong University Qilu Hospital
-
- You Bei-An
- Department of Geriatrics, Shandong University Qilu Hospital
-
- Cheng Mei
- Department of Geriatrics, Shandong University Qilu Hospital
Search this article
Abstract
Digitalis has been used to treat congestive heart failure for more than 200 years, although the dual effects (proliferation and death) induced by digitalis on cell growth have been known for many years, the mechanisms by which digitalis causes the actions were not completely known. The aim of this work was to characterize the proliferative effect of ouabain on cell growth in endothelial cells, and, to do the differential proteomic analysis of human umbilical vein endothelial cells (HUVEC) in response to ouabain and examine changes in protein expression. HUVEC were exposed to different concentrations (0.1—100 nM) of ouabain at 12—48 h intervals. Cell growth and morphological changes of HUVEC treated with ouabain were compared with cells under nontreated conditions. Ouabain stimulated HUVEC cell proliferation at low concentrations and induced cell death at higher concentrations. Using proteomics study, we identified 32 proteins of HUVEC with various important cellular functions and revealed 8 proteins such as Annexin A1, Annexin A2, Malate dehydrogenase, Myosin regulatory light chain 2 (MRLC2), Profilin-1, S100 calcium-binding protein A13, Triosephosphate isomerase and Translationally controlled tumor protein, regulated by low-dose ouabain treatment and MRLC2 was subsequently confirmed by Western blot. Our results give new insights into the cellular and molecular mechanisms of the proliferation action of low-dose ouabain on HUVEC and provide new avenues for the treatment of cardiovascular diseases.
Journal
-
- Biological and Pharmaceutical Bulletin
-
Biological and Pharmaceutical Bulletin 30 (2), 247-253, 2007
The Pharmaceutical Society of Japan
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282679602579840
-
- NII Article ID
- 110006162838
-
- NII Book ID
- AA10885497
-
- COI
- 1:CAS:528:DC%2BD2sXkvVSnu7k%3D
-
- ISSN
- 13475215
- 09186158
-
- NDL BIB ID
- 8616128
-
- PubMed
- 17268060
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed